Centessa Pharmaceuticals (NYSE: CNTA) — Perfil da empresa, notícias e dados financeiros
Centessa Pharmaceuticals is a biopharmaceutical company developing high-impact medicines across oncology, hematology, and immunology.
Centessa Pharmaceuticals
Centessa Pharmaceuticals (NASDAQ:CNTA) is a biopharmaceutical company focused on discovering, developing, and delivering high-impact medicines across a variety of diseases. With a unique approach to pharmaceutical development, Centessa aims to advance a broad portfolio of programs, each representing a novel concept that addresses unmet medical needs. The company's projects span a range of therapeutic areas, including oncology, hematology, immunology, and rare diseases, among others. Centessa's objective is to leverage its integrated research platform and deep scientific expertise to bring transformative treatments to patients around the world, aiming to improve outcomes and enhance lives by overcoming challenging health barriers.
Resumo
Operações
Produtos e/ou serviços de Centessa Pharmaceuticals
- LiFT (Liver Function Improvement) program, aiming to treat liver diseases through a novel therapeutic approach.
- Oncology project focused on developing targeted cancer therapies for unmet medical needs.
- Cardiovascular initiative dedicated to creating innovative solutions for heart disease management.
- Neuroscience venture exploring new pathways to address neurological disorders and improve brain health.
- Immunology effort aimed at discovering and developing treatments for autoimmune diseases.
- Regenerative medicine project leveraging stem cell research to repair and regenerate damaged tissues and organs.
equipe executiva do Centessa Pharmaceuticals
- Mr. John J. Crowley CPACFO & Principal Financial Officer
- Mr. Iqbal J. Hussain L.L.B.General Counsel, Chief Compliance Officer & Corporate Secretary
- Dr. Mario Alberto Accardi Ph.D.CEO & Director
- Mr. Raphael Deferiere CPAChief Accounting Officer & Principal Accounting Officer
- Ms. Tia L. BushChief Technology & Quality Officer
- Ms. Kristen K. Sheppard Esq., J.D.Senior Vice President of Investor Relations & Corporate Communications
- Ms. Karen M. AndersonChief People Officer
- Dr. Gregory M. Weinhoff M.B.A., M.D.Chief Business Officer
- Ms. Charlene StoudtSenior Vice President of Clinical Development Operations
- Dr. Stephen J. Kanes M.D., Ph.D.Head of R&D and Chief Medical Officer
Histórico de dividendos
Dividendos por ação pagos pela Centessa Pharmaceuticals , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $38.0000 |
Principais indicadores financeiros
Resultados divulgados pela Centessa Pharmaceuticals , em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 15 mi | -207,7 mi | -197,5 mi | |
| 0 | -201,1 mi | -235,8 mi | |
| 6,9 mi | -171,3 mi | -151,1 mi | |
| 0 | -212,3 mi | -216,2 mi |